A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

Abstract

The RR and PFS6 vary as a function of baseline prognostic factors in patients receiving second-line therapy for advanced UC. A nomogram incorporating prognostic factors facilitates the evaluation of outcomes across phase II trials enrolling heterogeneous populations and helps select suitable agents for phase III testing.